The Manufacturers Life Insurance Company Invests $2.38 Million in Palvella Therapeutics, Inc. $PVLA

The Manufacturers Life Insurance Company acquired a new stake in Palvella Therapeutics, Inc. (NASDAQ:PVLA) during the second quarter, Holdings Channel reports. The institutional investor acquired 15,545 shares of the company’s stock, valued at approximately $2,376,000.

A number of other institutional investors have also made changes to their positions in PVLA. Group One Trading LLC boosted its holdings in Palvella Therapeutics by 151.5% during the fourth quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after purchasing an additional 200 shares during the last quarter. KBC Group NV bought a new position in Palvella Therapeutics in the first quarter valued at $28,000. Northwestern Mutual Wealth Management Co. acquired a new stake in Palvella Therapeutics in the 2nd quarter valued at $35,000. Price T Rowe Associates Inc. MD increased its stake in Palvella Therapeutics by 11.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,090 shares of the company’s stock valued at $429,000 after buying an additional 433 shares during the last quarter. Finally, Quantbot Technologies LP bought a new stake in Palvella Therapeutics during the 2nd quarter worth about $71,000. Institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Price Performance

Shares of PVLA opened at $152.95 on Thursday. The company has a market cap of $2.20 billion, a PE ratio of -31.67 and a beta of -0.25. The firm has a 50-day moving average of $147.79 and a 200-day moving average of $128.75. Palvella Therapeutics, Inc. has a one year low of $51.38 and a one year high of $161.38.

Palvella Therapeutics (NASDAQ:PVLA) last issued its earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.35). Analysts expect that Palvella Therapeutics, Inc. will post -6.36 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on PVLA. Stephens restated an “overweight” rating and set a $220.00 price objective on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Chardan Capital raised Palvella Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. Canaccord Genuity Group set a $232.00 target price on Palvella Therapeutics in a report on Wednesday, August 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Palvella Therapeutics in a research report on Monday, June 29th. Finally, Truist Financial set a $207.00 price target on Palvella Therapeutics in a research note on Wednesday, August 5th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $209.14.

Insiders Place Their Bets

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $152.21, for a total transaction of $654,807.42. Following the transaction, the chief operating officer owned 2,154 shares of the company’s stock, valued at $327,860.34. The trade was a 66.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 17.20% of the stock is currently owned by company insiders.

Palvella Therapeutics Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.